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Introduction
Endothelial to mesenchymal transition (EndMT) is the process by 
which endothelial cells lose their cell-specific markers and morphology 
and acquire a mesenchymal cell-like phenotype. This process is 
regulated by a complex of several signaling pathways. EndMT plays a 
crucial role in the pathogenesis of various fibrotic diseases including 
interstitial pulmonary fibrosis, systemic sclerosis, as well as liver, heart 
and kidney fibrosis [1-4]. Elevated production and accumulation of 
collagen-rich extracellular matrix proteins occurs in various organs 
during the development and progression of pathological fibrosis, as well 
as in the stroma of many solid tumors [5-7]. Recent studies have shown 
that EndMT in the tumor microenvironment generates carcinoma-
associated fibroblasts [8] and may be essential for cancer progression. 
Activated fibroblasts formed during cardiac, renal, and lung fibrosis 
are of endothelial origin [9-11]. EndMT has also been implicated in 
pulmonary hypertension, wound healing and tumor fibrosis. Recent 
findings have suggested that Snail1 mediates the actions of endogenous 
TGF-β 1 signalssignaling that induces EndMT [12]. Pathological 
expression of Snail genes can be observed in fibrotic areas, for example, 
in the human kidneys. 
During EndMT, the endothelial cells lose markers, such as 
vascular-endothelial cadherin (VE-cadherin) and platelet endothelial 
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Abstract
The study uses global quantitative proteomics to investigate the molecular mechanisms behind the induction 
of endothelial-mesenchymal transition (EndMT) by transforming growth factor–β (TGF-β). Orbitrap Velos mass 
spectrometers and iTRAQ – a labeling-based analysis were used to perform a global and quantitative comparison 
of two proteomes of Human Microvascular Endothelial Cells-1 (HMEC-1) treated or not treated by TGF-β1. iTRAQ 
analysis identified 43 differentially-expressed proteins in the early stages of EndMT induced by TGF-β1. From 5522 
identified proteins, 26 were downregulated and 17 were upregulated, including proteins such as palladin, POTE I, 
torsin A and nucleoporin (NDC1). Further analysis of palladin revealed its increased mRNA and protein expression 
in response to TGF-β and Snail transcription factor. Our findings demonstrate that the newly- identified proteins may 
be involved in early stages of biological processes leading to EndMT.
Biological Significance: Endothelial to mesenchymal transition is a possible source of myofibroblasts, which 
play a crucial role in the pathogenesis of fibrosis. EndMT participate in tissue fibrotic processes in various organs. 
TGF-β family growth factors are involved in the initiation of EndMT. The intracellular cascades activated by TGF-β 
that result in the remarkable phenotypic change of endothelial cells to mesenchymal cells have not been entirely 
elucidated. The downstream signaling pathway initiated by TGF-β resulted in a strong upregulation of the Snail1 
transcriptional repressor. Our proteomics data demonstrated that TGF-β -induced EndMT leads to alterations in 
protein profiles, more specifically, the upregulation of palladin. This upregulation is mediated by Snail transcription 
factor and GSK-3 β signaling kinase. Our results also suggest that palladin could be considered a new biomarker in 
the early stages of cellular transdifferentiation, eventually leading to endothelial-mesenchymal transition. 
cell adhesion molecule-1 (PECAM-1), and gain mesenchymal markers, 
such as α-smooth muscle actin (α-SMA), fibroblast specific protein-1 
(FSP-1), neural-cadherin (N-cadherin) and vimentin. Resident 
endothelial cells leave the organized cell layer, lose cell–cell junctions, 
and acquire invasive and migratory properties. The TGF-β is a potent 
inducer of EndMT in several biological systems. In addition, it plays a 
crucial role in tissue fibrosis and is implicated in the pathogenesis of 
numerous fibrotic disorders [13].
Although several signaling pathways involved in TGF-β -induced 
EndMT have been identified to date, the precise mechanisms by 
which TGF-β converts an endothelial cell into a mesenchymal-like 
cell remain unclear. The aim of the present study is was to characterize 
the molecular mechanisms behind the early stages of EndMT by the 
quantitative proteomic analysis of cells EndMT.
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with a paper tissue. Next, the strip was divided to 18 fractions and 
labeled peptides were eluted from the gel (2 x 60 µl of 0.1% TFA in 2% 
acetonitrile, one hour with stirring).
LC–MS/MS analysis using C18 reverse phase chromatography
The separated peptides were applied to a nanoACQUITY UPLC 
Trapping Column (Waters) and then transferred to a 75 µm inner 
diameter, 250 mm-long nanoACQUITY UPLC BEH C18 Column 
(Waters) with a flow rate of 250 nl/minute. Column outlet was directly 
coupled to the Electrospray ionization (ESI) ion source of the Orbitrap 
Velos type mass spectrometer (Thermo Scientific), working in the 
regime of data dependent MS to MS/MS switch with HCD type peptide 
fragmentation. Other Orbitrap parameters were as follows: one MS scan 
was followed by a maximum of five MS/MS scans. Capillary voltage was 
1.5 kV, the results were acquired in a positive polarity mode. The MS/
MS spectra of peptides of each fraction were measured over 18 runs of 
three hours each.
The acquired MS/MS data were pre-processed with Mascot Distiller 
software (v.2.3, MatrixScience) and a search was performed with the 
Mascot Search Engine MatrixScience, Mascot Server 2.4) against 
the set of Human protein sequences (20348 sequence) derived from 
Sprot database (541954 sequences; 192668437 residues). The search 
parameters were set as follows: enzyme, semitrypsin; fixed modification, 
cysteine modification by MMTS, as well as iTRAQ labeling of the 
N-terminus of peptides and of lysine side chains; variable modifications 
- oxidation (M); max missed cleavages – 1.
This procedure provided q-value estimates for each peptide 
spectrum match (PSM) in the dataset. All PSMs with q-values 
>0.01 were removed from further analysis. A protein was regarded 
as confidently identified if at least two of its peptides were found. 
Proteins identified by a subset of peptides from another protein were 
excluded from analysis. The proteins that exactly matched the same set 
of peptides were combined into a single cluster. The mass calibration 
and data filtering were carried out with the developed in-house MScan 
software (http://proteom.ibb.waw.pl/mscan/). The lists of peptides that 
matched the acceptance criteria from the LC-MS/MS runs were merged 
into one common list.
Statistical significance was assessed with the Diffprot in-house 
software package [14,15]. The software determines the statistical 
validity of the regulation/expression status of the protein represented by 
its calculated protein ratio, based solely on the statistical analysis of the 
datasets from a given experiment, without assumptions on the character 
of the distribution of peptide ratios in a dataset (e.g. its normality). The 
probability of obtaining a given protein ratio by random selection from 
the dataset was tested by calculating protein ratios for a large number of 
permuted decoy datasets in which the peptide-protein assignment was 
scrambled. Calculated p-values were adjusted for multiple testing using 
a procedure controlling for false discovery rate (FDR). Only proteins 
with a q-value below 0.05 or those present in only one of two compared 
analytical groups were taken into consideration during further analysis.
Immunoblotting
The protein content of lysates was determined by the BCA method. 
Cell lysate aliquots containing appropriate equal total protein were 
boiled with 5x concentrated sample buffer, separated by SDS PAGE 
then electrophoretically transferred to nitrocellulose membrane 
(BioRad). Proteins were detected with the anti - SM22 (Thermo) 
and anti- claudin 1 (Cell Signaling) polyclonal antibodies and the 
anti- Snail 1 (Cell Signaling), anti - palladin (Novus), anti- vimentin 
Materials and Methods
Cell culture
Human Microvascular Endothelial Cells (HMEC-1) initially 
obtained from human foreskins were transfected with a PBR 322-based 
plasmid containing the coding region for the simian virus 40 large T 
antigen. The cell line was immortalized by Dr. Edwin Ades and Mr. 
Francisco J. Candal, both of CDC, and Dr. Thomas Lawley, of Emory 
University. HMEC-1 cells were provided by Jason Goldstein, PhD from 
the Center for Disease Control and Prevention, Atlanta, GA, USA. The 
base medium for this cell line was MCDB131 (without L-Glutamine) 
supplemented with: 10 ng/mL Epidermal Growth Factor (EGF); 1 µg/
mL Hydrocortisone; 2 mM L-glutamine; 10% Fetal Bovine Serum (FBS) 
and 100 units/ml Penicillin, 100 µg/ml Streptomycin. The cells reached 
90% confluence in the culture flask, trypsin–EDTA was used to remove 
them, and the cells were used in experiments or reseeded in another 
flask. The cells were incubated at 37°C in a humidified atmosphere of 
5% CO2.
Protein extraction and quantification
Before the experiment, HMEC-1 cells were starved in OptiMEM® I 
for 24 hours. TGF-β1 was then added at a concentration of 5 ng/ml for 
24 hours. The cells were next washed with Phosphate-buffered saline 
(PBS) and lysed with M-PER™ Mammalian Protein Extraction Reagent 
(Thermo Scientific™) on ice. After protein quantification using a BCA 
Protein Assay Kit (Pierce™), the proteins were precipitated, maintained 
in a with cold acetone for 24 hours at -20˚C, centrifuged and dried. 
Eight 100 µg samples (four controls and four samples after TGF-β1 
treatment) were prepared for quantitative analysis.
Trypsin digestion of protein and iTRAQ labeling
The protein samples were reconstituted in 20 µl dissolution buffer 
with 0.1% sodium lauryl (dodecyl) sulfate (SDS) and sonicated. Next 
the disulfide bonds of the proteins were reduced with 50 mM tris-(2-
carboxyethyl) phosphine (TCEP) for one hour at 60°C. The cysteine 
groups in the protein were then reversibly blocked by incubating with 
200 mM methyl methanethiosulfonate (MMTS) in isopropanol for 
10 minutes: these reagents were supplied as a part of the iTRAQ kit 
(Applied Biosystems).
The samples were digested overnight in trypsin (Promega) at 37°C 
on a rotary stirrer. After reconstitution, the digested peptides were 
labeled with another iTRAQ Reagent (113-121) for two hours at room 
temperature. Labeling was stopped by adding a sample buffer (8M urea, 
0.002% bromophenol blue in 50 mM Tris-HCl, pH 8.0), according 
to the iTRAQ manufacturer’s protocol. For LC-MS/MS experiment 
iTRAQ-labeled samples were combined and concentrated for the IPG 
strip (SpeedVac™ Concentrator).
The labeled peptides were separated according to the isoelectric 
point in Immobiline DryStrip gels (IPG strips). Each sample was applied 
to 18  cm IPG strip with 3–11 NL pH gradients (GE Healthcare) for 
isoelectrofocusing (IEF), using 340 µl of sample/strip, corresponding to 
400 µg protein. The IPG strip was rehydrated overnight in an IPG box 
(GE Healthcare).
The next day, the strips were isoelectrofocused using an Ettan 
IPGphor 3 electrophoresis system (GE Healthcare) as follows. A five-
hour pre-run was performed at 500V. Following this, a long gradient 
focusing program was used: one hour at 500 V, nine hours at 1000 V 
and 30 hours at 8000 V (the final current was 5 µA). After focusing, 
the strip was removed from the tray and the overlay oil was blotted 
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(Sigma), anti - α-tubulin (Sigma) and HRP conjugate anti - GAPDH 
(Santa Cruz Biotechnology) monoclonal antibodies. Immunodetection 
was performed using an enhanced chemiluminescence kit (ECL Kit, 
PIERCE), with the resulting Kodak BioMax Light Films (Eastman 
Kodak, Rochester, NY, USA) scanned. The protein extracts and the 
control lysate from human Snail-transfected 293T cells (Santa Cruz 
Biotechnology) were used as controls.
Real-time PCR
Total RNA of HMEC-1 cells was isolated using Trizol® (Invitrogen) 
according to the manufacturer's instructions. Determination of RNA 
quality was performed on an Agilent 2100 Bioanalyzer (Agilent 
Technologies). Reverse transcription was performed at 50°C for 30 
minutes with 1 μg of total RNA and the Maxima First Strand cDNA 
synthesis kit with double strand DNAse (Thermo Scientific). Real-
time PCR experiments were performed on an Mx3005P thermocycler 
(Agilent Technologies) with Maxima SYBR Green/ROX qPCR Master 
Mix (Thermo Scientific) and specific primers for human Snail1, 
PECAM, VE-cadherin, FSP-1, integrin subunit α11 and SM22α 
(transgelin). Primer sequences and sizes of the PCR product for each 
targeted gene are described in Table 1. Each sample was normalized to 
the GAPDH housekeeping gene. The ΔΔCt method was used for the 
relative quantification. PCR assays were conducted in triplicate for each 
sample.
Confocal microscopy
HMEC-1 cells were seeded at a concentration of 1 × 104 cells per 
well on a 96-well SCREENSTAR microplate (Greiner Bio-One). After 24 
hours, control and TGF-β1-stimulated cells were fixed using methanol-
free 1% formaldehyde solution (Thermo Scientific Pierce) and blocked 
for one hour at room temperature using 3% BSA solution prepared in 
PHEM buffer (60 mM PIPES, pH 6.9, 25 mM HEPES, 10 mM EGTA, 
4 mM MgCl2). Subsequently, the cells were incubated overnight at 4oC 
with respective primary antibodies anti-PECAM conjugated with FITC 
(BD Pharmingen), anti-vimentin (Sigma), anti-Snail (Cell Signaling) 
diluted in 1% BSA/PHEM. Finally, cells were washed three times with 
PHEM buffer, stained for one hour at room temperature with respective 
secondary antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 
568 (Invitrogen) prepared in 1% BSA/PHEM and again washed three 
times with PHEM buffer. Cell nuclei were counterstained for 15 minutes 
with 5 µM Hoechst33342 dye, and the cells were stored refrigerated and 
protected from light in PHEM buffer until imaging.
All confocal microscopy images were obtained under 6300x 
magnification with an LSM780 microscope equipped with a Plan-
Apochromat 63x/1,4 Oil DIC M27 objective, 405 nm laser diode and 
InTune™ tunable excitation laser system (Carl Zeiss; Oberkochen, 
Germany). 
Statistical analysis
Data are presented as mean ± standard deviation. The results were 
repeated with at least three independent experiments. Statistical analyses 
were performed using unpaired t-test for two-group comparisons and 
the Tukey test following one-way ANOVA test for multiple groups. 
Results
TGF-β regulates the expression of mesenchymal markers
To better understand the role of TGF-β signaling in initiating 
EndMT, TGF-β -induced proteomic changes were identified in a line of 
human dermal microvascular endothelial cells (HMEC-1) using global 
quantitative proteomics methods. HMEC-1 express various endothelial 
markers, including PECAM, and Claudin1, whereas mesenchymal cells 
express others: transgelin (SM22α), vimentin, fibronectin, collagens 
and smooth muscle cell actin (SMA). Several transcription factors are 
involved in EndMT transition, including the Snail repressor. HMEC-1 
were treated for 48 hours with TGF-β1 at concentrations ranging from 1 
to 50 ng/ml after 24 hours serum starvation (Figure 1A). Stimulation of 
HMEC-1 cells with TGF-β1 induced expression of Snail transcription 
factor, which was confirmed by immunoblotting (Figure 1A) and Real-
time quantitative PCR (Figure 1B).
TGF-β1 was found to have a dose-dependent effect on the expression 
of Snail1. The highest level of Snail was reached in the presence of 10 
ng/ml of TGF-β1. The initial changes in the Snail expression were 
observed at a TGF-β1 concentration of 5 ng/ml, which was then used 
in the following experiment. Real-time quantitative PCR examination 
found that HMEC-1 treated with 5 ng/ml TGF-β1 for 24 or 48 hours 
increased Snail mRNA levels (Figure 1C).
Light microscope morphological examination of HMEC-1 revealed 
a slight change from an endothelial morphology to fibroblast-like 
morphology following treatment with TGF-β1 for 48 hours (Figure 
1D). No significant changes in cell morphology were observed in early 
stages of EndMT. 
Immunoblotting was performed to assess the protein expression of 
the endothelial markers: VE cadherin, claudin1 and the mesenchymal 
markers: vimentin, SM22α and α11 integrin, as well as the control 
markers: tubulin and GAPDH. TGF-β1 treatment caused decreased 
protein expression of VE cadherin and claudin-1, greater expression of 
SM22α and vimentin, and slightly elevated expression of α11integrin 
(Figure 2A).
Real-time quantitative PCR was performed to assess gene 
expression of endothelial markers (claudin1, PECAM, VE-cadherin) 
and mesenchymal markers (FSP-1, α11, SM22α) in HMEC1 treated 
by TGF-β1 (Figure 2B). Treatment of HMEC-1 with TGF-β1 for 48 
hours confirmed decreased levels of endothelial markers and increased 
expression of mesenchymal markers.
Finally confocal microscope examination found that TGF-β1 
induced mesenchymal marker expression and decreased endothelial 
marker expression. To detect the endothelial marker (PECAM) and 
the mesenchymal marker (vimentin), the cells were stimulated with 
TGF-β1 for 24 hours and then treated with anti-PECAM antibody 
Genes Primer Sequences
α11
F: CACGACATCAGTGGCAATAAG
R: GACCCTTCCCAGGTTGAGTT
Claudin-1
F: TTGACTCCTTGCTGAATCTGAG
R: TTCTGCACCTCATCGTCTTC
GAPDH
F: CCATCACCATCTTCCAGGAGCG
R: GAGAGATGATGACCCTTTTGGC
FSP-1
F: ACTTGGACAGCAACAGGGAC
R: GCTGCTTATCTGGGAAGCCT
PECAM
F: GACGTGCAGTACACGGAAGT
R: TCTGCTTTCCACGGCATCAG
Snail
F: GCT GCA GGA CTC TAA TCC AGA
R: ATC TCC GGA GGT GGG ATG
SM22 α
F: TCAGATGGGCAGCAACAGAG
R: GCCAAGGCAGTGATGCTTTC
VE-Cadherin
F: TGGTCACCCATGCATCTTCC
R: CCATGACGAAGGGTGAGCTT
Table 1: PCR primer sequences.
Citation: Stasiak M, Gawryś K, Popielarski M, Bednarek R, Studzian M, et al. (2017) Differential Quantitative Proteomics of Human Microvascular 
Endothelial Cells 1 by iTRAQ Reveals Palladin to be a New Biomarker During TGF-β1 Induced Endothelial Mesenchymal Transition. J 
Proteomics Bioinform 10: 236-245. doi: 10.4172/jpb.1000447
Volume 10(10) 236-245 (2017) - 239 J Proteomics Bioinform, an open access journal ISSN: 0974-276X
conjugated with FITC or with anti-vimentin antibody, followed by a 
secondary antibody conjugated with Alexa Fluor (Figure 2C). This 
application of TGF-β1 was found to be sufficient to induce EndMT.
Analysis of differentially expressed proteins during TGF-β1 
induced EndMT in HMEC-1 
iTRAQ labeling followed by nL-LC-MS/MS analysis, with Orbitrap 
Velos mass spectrometers, was used to quantitatively profile global 
protein expression. The peptides were labeled with isobaric chemical 
tags and a global quantitative comparison of two proteomes was 
performed using a total number of 5522 proteins. A total of 43 proteins 
were observed to be significantly differentially expressed between the 
treated and untreated samples (P<0.05). Of these, 17 were overexpressed 
and 26 were down-regulated after TGF-β1 stimulation (Table 2).
Of the 17 up-regulated proteins (Table 2A), nucleoporin NDC1, 
POTE I, torsin A and palladin are of special interest for the biology 
of EndMT. Of the 26 down-regulated proteins (Table 2B) debrin-
like protein (DBNL) and alpha crystallin B (αB crystallin) were of 
interest. Some of the down-regulated proteins, such as STAT1, IFIT3, 
IFIT1, GBP1, OAS2, OAS3, ISG15, UBE2L6, MX1 and DDX58, can be 
involved in negative regulation of EndMT.
Biological function
Proteomic analysis was used to determine the distribution of 
overexpressed proteins according to biological processes. Of the 5522 
identified proteins, only 43 were significantly modulated by TGF-β 1 
treatment (P<0.05). The functional significance of the proteins, their 
localization in cellular components (Figure 3) and their possible role in 
biological processes (Figure 4) were examined during 24-hour TGF-β1 
treatment.
A search of the String 10.0 database (Search Tool for Analysis of 
Interacting Gens/Proteins) found the identified proteins to be involved 
in a number of biological processes, including response to stimulus 
(POTEI, AKAP12, DAB2, DBNL, DDX58, OAS2, OAS3), response to 
stress (DBNL, DDX58, OAS2, OAS3, MX1, POTE I, STAT1, STIP1), 
cellular response to cytokine stimulus (GBA, GPBP1, IFTI1, ISG1, 
MX1, STAT1), the cytokine-mediated signaling pathway (IFTI1, 
IFTI3, ISG15, MX1, STAT1). TGF-β1 mediates reorganization in 
cytoskeleton during EndMT, which is expressed as dynamic changes in 
cell morphology. The identified upregulated proteins are components 
of cell junctions (PALLD, AKAP12, DAB2, DBNL, DDX58, TOR1A, 
LAP3, LASP1, LIMA1), cytoskeleton (DBNL, DDX58, POTEI, PALLD, 
MYO1D, SLC2A1) and play a role in focal adhesion (AKAP12, DAB2, 
PALLD, LAP3, LASP1) (Figure 4). The upregulated proteins: palladin, 
POTEI and torsin A participate in the regulation of cytoskeleton 
reorganization.
Protein-protein interaction proteomic network analysis
String10.0 was also used for functional interpretation of the 
differentially expressed proteins for cellular processes. Direct 
interaction network analysis revealed interactions between. PALLD, 
POTEI, DBNL and MYO1D, which are involved in initiation of fibrosis, 
cancerogenesis, cell migration and cytoskeleton reorganization (Figure 
5). Moreover, direct interactions were also identified between several 
proteins which were found to be downregulated, including STAT1, 
IFIT3, IFIT1, GBP1, OAS2, OAS3, ISG15, UBE2L6, MX1 and DDX58. 
These results suggest that these proteins may be involved in the negative 
regulation of early stages of EndMT initiated by TGF-β 1. Interestingly, 
although POTEI was upregulated, it was found to interact with some 
downregulated proteins (OAS2, OAS1, MX1, ISG15) following TGF-β 
1 stimulation.
Figure 1: (A) Western blot analysis of Snail expression in TGF-β1 treated HMEC-1 cells. Upper numbers indicate the value by densitometry normalized to control. 
(B and C) Quantitative RT-PCR analysis of Snail mRNA levels normalized to GAPDH in HMEC-1 cells depending on the time of stimulation (C) and concentration 
(B) of TGF-β1. Data are presented as mean ± SD from three independent experiments. Significance of statistical differences between control and treated TGFβ1 
is at P<0.05. (D) Morphology (representative pictures) of HMEC-1 cells treated and untreated with TGF-β1 as observed by phase contrast microscopy (scale bar, 
10 μm).
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Figure 2: (A) Western blot analysis of VE-cadherin, claudin1, vimentin, SM22α and α11 expression in control and TGF-β1 treated for 48 hours HMEC-1 cells. Upper 
numbers indicate the value by densitometry normalized to control. The blots are representative of three independent experiments. (B) Relative claudin1, PECAM, 
VE-cadherin, FSP-1, α11, and SM22α mRNA expression in control (NT) and TGF-β1 treated HMEC-1 cells. Results shown as mean with SD. Asterisk (*) indicates 
statistically significant differences between control and treated TGFβ1 cells) (* P<0.05; ** P<0.01). (C) Subcellular location and expression level of vimentin and 
PECAM in TGF-β1 treated and untreated (NT) HMEC-1 cells examined by immunofluorescence and shown as representative confocal microscopy images (green 
pseudocolor). Cell nuclei (blue pseudocolor) were counterstained with Hoechst33342 dye.
A
No Protein Protein 
score
Coverage Qvalue Ratio Fold 
change
Peptides Description
1 P50443 292 9.34 0.00053 1.57 1.57 6 Sulfate transporter OS=Homo sapiens GN=SLC26A2
2 Q9Y241 186 25.81 0.0072 1.5 1.5 3 HIG1 domain family member 1A, mitochondrial OS=Homo sapiens GN=HIGD1A
3 Q9HCJ1 130 9.15 0.02238 1.47 1.47 3 Progressive ankylosis protein homolog OS=Homo sapiens GN=ANKH
4 P11166 361 12.4 0.00391 1.45 1.45 6 Solute carrier family 2, facilitated glucose transporter member 1 OS=Homo 
sapiens GN=SLC2A1
5 Q9BTX1 229 7.86 0.00873 1.39 1.39 4 Nucleoporin NDC1 OS=Homo sapiens GN=NDC1
6 Q9NUN7 203 6.74 0.04612 1.39 1.39 3 Alkaline ceramidase 3 OS=Homo sapiens GN=ACER3
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GAPDH expression was used to allow equal loading of all proteins. The 
expression of palladin at the protein (Figure 6D) and mRNA (Figure 
6A) levels was found to be significantly increased following TGF-β1 
treatment. 
Snail regulates Palladin expression 
Recent studies have revealed that Snail transcription factors are 
involved in EndMT. The downstream signaling pathway initiated by 
TGF-β resulted in strong upregulation of the transcriptional repressor 
Enhanced expression of Palladin potentially contributes to 
TGF-β induced EndMT
Among the 17 proteins found to be upregulated following TGF-β 
1 treatment, palladin is of particular interest (Figure 6). Differential 
expression was confirmed using Western blotting. The HMEC-1 
cells were cultured in absence or presence of 5 ng/mL of TGF-β1 for 
48 hours. Cells were starved of serum for 24 hours prior to TGF-β1 
treatment. The cell lysates were prepared and analyzed for palladin. 
7 Q9NR50 101 9.51 0.01994 1.29 1.29 4 Translation initiation factor eIF-2B subunit gamma OS=Homo sapiens 
GN=EIF2B3
8 O14656 748 24.1 0.01899 1.27 1.27 8 Torsin-1A OS=Homo sapiens GN=TOR1A
9 P0CG38 13567 14.14 0.04126 1.24 1.24 5 POTE ankyrin domain family member I OS=Homo sapiens GN=POTEI
10 Q8WX93 306 7.45 0.00168 1.23 1.23 9 Palladin OS=Homo sapiens GN=PALLD
11 O94832 289 8.55 0.04409 1.19 1.19 6 Unconventional myosin-Id OS=Homo sapiens GN=MYO1D
12 O75531 1600 46.07 0.04191 1.18 1.18 8 Barrier-to-autointegration factor OS=Homo sapiens GN=BANF1
13 P05141 5270 44.63 0.04894 1.17 1.17 7 ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5
14 Q70CQ2 859 4.31 0.01846 1.15 1.15 11 Ubiquitin carboxyl-terminal hydrolase 34 OS=Homo sapiens GN=USP34
15 P04062 856 23.32 0.02935 1.15 1.15 10 Glucosylceramidase OS=Homo sapiens GN=GBA
16 O60701 1439 40.49 0.04184 1.13 1.13 17 UDP-glucose 6-dehydrogenase OS=Homo sapiens GN=UGDH
17 Q9Y617 754 31.08 0.03203 1.1 1.1 14 Phosphoserine aminotransferase OS=Homo sapiens GN=PSAT1
B
No Protein Protein 
score
Coverage Qvalue Ratio Fold 
change
Peptides Description
1 P20591 6096 54.98 0.00053 0.66 1.52 31 Interferon-induced GTP-binding protein Mx1 OS=Homo sapiens GN=MX1
2 P05161 1103 67.27 0.00053 0.68 1.47 7 Ubiquitin-like protein ISG15 OS=Homo sapiens GN=ISG15
3 P02511 205 17.71 0.00222 0.7 1.44 4 Alpha-crystallin B chain OS=Homo sapiens GN=CRYAB
4 P29728 246 8.48 0.00148 0.71 1.4 5 2'-5'-oligoadenylate synthase 2 OS=Homo sapiens GN=OAS2
5 P09914 608 21.76 0.00053 0.74 1.35 9 Interferon-induced protein with tetratricopeptide repeats 1 OS=Homo sapiens 
GN=IFIT1
6 P32455 726 17.74 0.00082 0.75 1.33 6 Interferon-induced guanylate-binding protein 1 OS=Homo sapiens GN=GBP1
7 O14933 589 26.8 0.04171 0.77 1.3 4 Ubiquitin/ISG15-conjugating enzyme E2 L6 OS=Homo sapiens GN=UBE2L6
8 P30685 1230 32.6 0.00222 0.78 1.29 5 HLA class I histocompatibility antigen, B-35 alpha chain OS=Homo sapiens 
GN=HLA-B
P30491 1230 32.6 HLA class I histocompatibility antigen, B-53 alpha chain OS=Homo sapiens 
GN=HLA-B
P10319 1250 33.43 HLA class I histocompatibility antigen, B-58 alpha chain OS=Homo sapiens 
GN=HLA-B
9 Q15847 697 69.74 0.03273 0.79 1.26 4 Adipogenesis regulatory factor OS=Homo sapiens GN=ADIRF
10 Q9Y3Z3 1603 35.14 0.00053 0.8 1.25 19 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 OS=Homo 
sapiens GN=SAMHD1
11 O14879 452 27.35 0.01977 0.8 1.26 5 Interferon-induced protein with tetratricopeptide repeats 3 OS=Homo sapiens 
GN=IFIT3
12 P42224 4026 45.47 0.00053 0.81 1.23 28 Signal transducer and activator of transcription 1-alpha/beta OS=Homo sapiens 
GN=STAT1
13 P67809 2499 47.22 0.00185 0.81 1.23 10 Nuclease-sensitive element-binding protein 1 OS=Homo sapiens GN=YBX1
14 O95786 364 10.92 0.00082 0.83 1.2 8 Probable ATP-dependent RNA helicase DDX58 OS=Homo sapiens GN=DDX58
15 Q9UHB6 473 16.34 0.04216 0.84 1.19 8 LIM domain and actin-binding protein 1 OS=Homo sapiens GN=LIMA1
16 Q08380 72 6.15 0.03776 0.85 1.17 5 Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP
17 Q9Y6K5 439 12.33 0.01797 0.86 1.16 8 2'-5'-oligoadenylate synthase 3 OS=Homo sapiens GN=OAS3
18 P98082 655 12.73 0.04608 0.87 1.15 8 Disabled homolog 2 OS=Homo sapiens GN=DAB2
19 Q63HN8 3192 11.22 0.00053 0.88 1.14 51 E3 ubiquitin-protein ligase RNF213 OS=Homo sapiens GN=RNF213
20 Q14847 1989 51.72 0.01873 0.88 1.13 23 LIM and SH3 domain protein 1 OS=Homo sapiens GN=LASP1
21 Q06323 3855 64.26 0.028 0.88 1.13 20 Proteasome activator complex subunit 1 OS=Homo sapiens GN=PSME1
22 P28838 2894 47.01 0.00873 0.89 1.12 22 Cytosol aminopeptidase OS=Homo sapiens GN=LAP3
23 Q9UJU6 818 21.86 0.00851 0.9 1.12 12 Drebrin-like protein OS=Homo sapiens GN=DBNL
24 O00151 1528 48.63 0.01873 0.9 1.11 16 PDZ and LIM domain protein 1 OS=Homo sapiens GN=PDLIM1
25 Q02952 6553 34.79 0.00466 0.91 1.1 35 A-kinase anchor protein 12 OS=Homo sapiens GN=AKAP12
26 P31948 1783 39.41 0.02046 0.93 1.07 30 Stress-induced-phosphoprotein 1 OS=Homo sapiens GN=STIP1
Table 2: List of proteins in HMEC-1 found to be significantly differentially expressed in response to TGF-β1 by iTRAQ analysis. (A) up-regulated (B) down-regulated.
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Snail. To determine whether Snail expression has an effect on palladin 
induction, HMEC-1 were transfected with a pcDNA-Snail expression 
plasmid for 48 hours. Snail expression was found to increase in cells 
transfected with the Snail expression vector (Figure 6G). No significant 
changes in palladin expression were observed at the protein level (Figure 
6E); however, increased mRNA levels were found in cells transfected 
with the Snail expression plasmid (Figure 6B).
Overexpression of Snail was sufficient to induce EMT (epithelial 
to mesenchymal transition), but Snail expression alone was insufficient 
for EndMT. The Snail inhibitor GSK-3β needs to be inhibited by 
phosphorylation with a kinase such as AKT to induce EndMT. To 
determine whether inhibition of GSK-3β leads to increased expression 
of palladin, a chemical inhibitor of GSK-3β, lithium chloride (LiCl), 
was used. Cells transfected with Snail expression plasmid and then 
treated with LiCl show increased palladin expression at both the protein 
(Figure 6C) and mRNA levels (Figure 6F). These results suggest that 
the GSK-3β inhibition was involved in the up regulation of palladin 
expression by the Snail transcription factor and by the EndMT process.
Figure 3: Classification of differently expressed proteins with numbers of respective proteins according to the cellular localizations Gene Ontology (GO). The 
analysis was performed using the String 10.0 database with a minimum false discovery rate PFDR<0.05. The numbers refer to the number of proteins corresponding 
to the respective GO terminology.
Figure 4: Occurrence of biological processes assigned to our EndMT model. The analysis was performed using the Siring 10.0 database. The numbers refer to the 
number of proteins corresponding to the respective GO term.
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Figure 5: Biological network analysis of differentially expressed proteins in response to TGF-β1 by String pathway mapping tool. Direct interaction network of 
differentially expressed proteins identified by iTRAQ analysis in response to TGF-β1 treatment. The lines connecting the nodes indicate only direct binding protein-
protein interactions. Protein names for nonobvious symbols are as follows: STAT1 (signal transducer and activator of transcription 1), IFIT3 (interferon-induced 
protein with tetratricopeptide repeats 3), GBP1 (interferon-induced guanylate-binding protein 1), DDX58 (probable ATP-dependent RNA helicase), IFIT1 (interferon-
induced protein with tetratricopeptide repeats 1), UBE2L6 (ubiquitin/ISG15-conjugating enzyme E2 L6), ISG15 (ubiquitin-like protein ISG15), MX1 (interferon-
induced GTP-binding protein Mx1), OAS3 (2’-5’-oligoadenylate synthetase 3), OAS2 (2’-5’-oligoadenylate synthetase 2), POTEI (POTE ankyrin domain family 
member I), MYO1D (unconventional myosin-Id), DBNL (drebrin-like protein), SLC2A1 (solute carrier family 2, facilitated glucose transporter member 1).
Figure 6: Quantitative RT-PCR analysis of palladin mRNA levels normalized to GAPDH in HMEC-1 cells: not treated and treated with TGFβ1 (A), transiently 
transfected with pcDNA or pcDNA-Snail (B), transiently transfected with pcDNA or pcDNA-Snail and next treated with LiCl (C). Western blot analysis of palladin 
expression in HMEC-1 cells: TGFβ1 treated (D) and transiently transfected with Snail (E), transiently transfected with Snail and treated with LiCl (F) (Data are 
presented as mean ± SD from three independent experiments. Asterisk (*) indicates statistically significant differences between control and treated TGFβ1 cells) (* 
P<0.05). (G) Subcellular location of vimentin (green pseudocolor) and Snail (red pseudocolor) in HMEC-1 cells transfected with pcDNA and pcDNA-Snail examined 
by immunofluorescence and shown as representative confocal microscopy images. Cell nuclei (blue pseudocolor) were counterstained with Hoechst33342 dye.
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Discussion
Our data provides a novel insight into the molecular mechanisms 
that mediate early stages of EndMT. The results of the iTRAQ method 
highlight differences in protein profile between HMEC-1 cells treated 
with TGF-β1 and those untreated control cells. TGF-β1 treatment 
was found to promote the expression of 17 proteins, four of which are 
essential for inducing EndMT: palladin, torsin A, nucleoporin –NDC1 
and POTE I. Furthermore, TGF-β1 increases the expression of the 
Snail transcription factor, which then activates the pathway leading to 
palladin expression.
Recent studies have highlighted the involvement of the TGF-β 
family of growth factors in the initiation of EndMT, but the molecular 
and the intracellular pathways activated by TGF-β that result in EndMT 
still remain unclear. Studies on primary murine pulmonary endothelial 
cells [16] and cultured human dermal microvascular cells [17] have 
demonstrated that EndMT involves both Smad-dependent and Smad-
independent pathways. The molecular mechanism inducing EndMT 
by TGF-β has been found to involve the Snail family of transcription 
repressors. In mouse embryonic stem cell-derived endothelial cells, 
TGF-β induced EndMT and Snail expression [11].
Four proteins, which may be important in the biology of End MT, 
were chosen: NDC1, POTE I, torsin A and palladin. Nucleoporin 1 
(NDC1) level was found to be up-regulated following 48-hour TGF-β 
1 treatment. The proteomic analysis indicated significant, 1.39-fold 
upregulation of nucleoporin NDC1. Upregulation of nucleoporin 
NDC1 in the early stages of EndMT may suggest that it plays a role 
in progression. The nuclear envelope contains thousands of pores, 
these being sites for the movement of molecules between nucleus and 
cytoplasm determined by large macromolecular assemblies known as 
nucleopore complexes (NPC) [18]. The NPC consists of more than 
30 evolutionarily conserved nucleoporins, each with a particular 
localization within nuclear envelope [19-21]. TGF-β induces the 
phosphorylation of the Smad proteins and drives Smads into the 
nucleus via the nuclear pore complex (NPC) [22,23]. The proteomic 
profile data revealed increased expression of one nucleoporin isoform, 
nucleoporin1 (NDC1), which confirms that Smad-dependent pathways 
are induced by TGF-β1 in the early stages of EndMT.
POTE I (POTE ankyrin domain family, member I) is another newly 
identified antigen overexpressed in EndMT transition. In humans the 
POTE gene family consists of 13 highly homologous members located 
on eight different chromosomes [24]. Previous studies have shown that 
POTE molecules are localized in the cytoplasm towards the inner part 
of the cellular membrane. POTE E is a dominant subtype expressed in 
many cancers including those of the prostate, colon, lung, breast, ovary, 
and pancreas and many as well as in numerous cancer cell lines [25,26]. 
POTE proteins expressed in cancer may have roles in cytoskeletal 
structure [27] but their exact function is unknown. 
The next newly-identified protein upregulated by TGF-β1 in 
HMEC-1 is torsin A: a member of the AAA+ ATPase superfamily 
located within the lumen of the nuclear envelope and endoplasmic 
reticulum, which interacts with transmembrane proteins [28]. Torsin 
A is associated with laminin-associated polypeptide 1 (LAP1), 
conventional kinesin light chain 1 (KLC1), vimentin and actin. Torsin 
A occurs in complex with nesprin-plectin-vimentin in fibroblast and 
also has a role in nuclear dynamics via its association with nesprins and 
cytoskeleton. Torsin A was found to be associated with the cytoskeleton 
in fibroblasts by interaction with vimentin [29].
Significant overexpression of palladin was observed in the HMEC-
1 cells transfected with Snail expression vector or treated by TGF-β1. 
The important changes in palladin expression during stimulation by 
TGF-β1 may represent an essential step in determining the morphology 
and actin organization of endothelial cells in EndMT transition.
Palladin is a multi-domain, actin-binding protein which binds 
directly to F-actin and many other actin-binding proteins, including 
profilin, VASP, ezrin, Lasp-1, EPS8, CLP-36, α-actinin and ArgBP2 [30-
37]. Palladin is a cytoskeletal protein that controls stress fiber integrity, 
and is expressed in epithelial and mesenchymal cells [38,39].
TGF-β induced upregulation of palladin is mediated by Smad and 
mitogen-activated protein kinase pathways [38]. The downregulation of 
palladin leads to the disruption of actin-containing stress fibers, whereas 
upregulation leads to re-organization of the actin cytoskeleton and 
induction of thick actin bundles [38]. Palladin levels are up-regulated 
in metastatic cancer cells and play an important role in organizing actin 
arrays within migrating cells and in invasive motility [32]. The palladin 
gene was found within a cluster of invasion-specific genes in pancreatic 
and colorectal cancers [40-42]. The palladin protein levels increase 
significantly in human dermal fibroblasts in response to TGF-β 1 
treatment, and during myofibroblast differentiation in the presence of 
TGF-β1 [39]. TGF-β increased palladin expression in human corneal 
fibroblasts in a manner dependent on Smad and MAPK signaling. 
Moreover, palladin was required for the TGF-β–induced upregulation 
of α-SMA [43]. Palladin activates fibroblasts inducing them to become 
myofibroblasts. The tumor-associated fibroblasts express palladin very 
early in tumorigenesis. In the early stages of neoplastic progression 
in pancreatic tumorigenesis, palladin expression levels in stromal 
fibroblasts increased and co-localized with α-SMA [44]. Palladin was 
found to be overexpressed in cancer-associated fibroblasts of different 
types of tumors such as pancreas, breast, lung, kidney, and ovary, 
promoting their invasion and metastasis [39].
Our findings very are the first to indicate that palladin is involved 
in the early stages of EndMT in HMEC-1 treated by TGF-β1. The 
upregulation of palladin is mediated by the Snail and GSK- β signaling 
pathways. Therefore, palladin may act as a potential biomarker in the 
early stages of EndMT.
Conclusion
Our study demonstrated that exposure of HMEC-1 to TGF-β 1 
induced differential expression of proteins that mediate in the early 
stages of EndMT. A proteomic profile of endothelial cells leading to 
differentiation into a mesenchymal phenotype showed that some of 
the 17 overexpressed proteins, such as palladin, torsin A, nuleoporin1 
and POTE I, could be considered essential in EndMT. In addition, the 
Snail and GSK- β signaling pathways were shown to be involved in 
the upregulation of palladin in TGF-β -induced EndMT. Our results 
identified palladin as a novel marker in EndMT.
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